IQVIA’s (IQV) Equal Weight Rating Reaffirmed at Barclays

Barclays reiterated their equal weight rating on shares of IQVIA (NYSE:IQV) in a research note released on Thursday, MarketBeat.com reports. Barclays currently has a $170.00 price objective on the medical research company’s stock, down from their previous price objective of $235.00.

A number of other equities research analysts also recently issued reports on the company. Stephens assumed coverage on IQVIA in a research report on Friday, December 20th. They set an “overweight” rating and a $250.00 price objective on the stock. Morgan Stanley increased their price target on IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a report on Tuesday, February 11th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $270.00 price objective on shares of IQVIA in a research note on Monday, February 10th. StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Wednesday, March 12th. Finally, William Blair reiterated an “outperform” rating on shares of IQVIA in a report on Wednesday, December 11th. Six equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $241.50.

IQVIA Stock Up 1.5 %

NYSE IQV opened at $145.40 on Thursday. The stock has a 50 day moving average price of $182.32 and a 200-day moving average price of $199.64. IQVIA has a one year low of $135.97 and a one year high of $252.88. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The company has a market capitalization of $25.64 billion, a P/E ratio of 19.39, a P/E/G ratio of 1.99 and a beta of 1.46.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, equities analysts predict that IQVIA will post 10.84 EPS for the current fiscal year.

Institutional Investors Weigh In On IQVIA

Several hedge funds have recently made changes to their positions in IQV. Smith Group Asset Management LLC bought a new position in shares of IQVIA during the fourth quarter valued at approximately $1,616,000. Nordea Investment Management AB lifted its holdings in IQVIA by 47.4% during the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after buying an additional 452,029 shares during the period. Hickory Asset Management Inc. bought a new stake in IQVIA during the 4th quarter valued at $941,000. Fifth Third Bancorp increased its holdings in shares of IQVIA by 13.0% in the 4th quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company’s stock valued at $2,590,000 after acquiring an additional 1,521 shares during the period. Finally, Graphene Investments SAS raised its position in shares of IQVIA by 22.0% in the 4th quarter. Graphene Investments SAS now owns 15,000 shares of the medical research company’s stock worth $2,948,000 after acquiring an additional 2,700 shares in the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.